反応式
[F:1][C:2]1[CH:3]=[C:4]([C:8]2([CH2:14][CH2:15][N:16]3[C@H:21]4[CH2:22][CH2:23][C@@H:17]3[CH2:18][CH:19]([N:24]3[C:28]5[CH:29]=[CH:30][CH:31]=[CH:32][C:27]=5[N:26]=[C:25]3[CH3:33])[CH2:20]4)[CH2:13][CH2:12][NH:11][CH2:10][CH2:9]2)[CH:5]=[CH:6][CH:7]=1.[Cl:34][C:35]1[CH:43]=[C:42]([F:44])[C:41]([S:45]([NH:48][CH3:49])(=[O:47])=[O:46])=[CH:40][C:36]=1[C:37](O)=[O:38]>>[Cl:34][C:35]1[C:36]([C:37]([N:11]2[CH2:10][CH2:9][C:8]([C:4]3[CH:5]=[CH:6][CH:7]=[C:2]([F:1])[CH:3]=3)([CH2:14][CH2:15][N:16]3[C@H:21]4[CH2:22][CH2:23][C@@H:17]3[CH2:18][CH:19]([N:24]3[C:28]5[CH:29]=[CH:30][CH:31]=[CH:32][C:27]=5[N:26]=[C:25]3[CH3:33])[CH2:20]4)[CH2:13][CH2:12]2)=[O:38])=[CH:40][C:41]([S:45]([NH:48][CH3:49])(=[O:46])=[O:47])=[C:42]([F:44])[CH:43]=1参加物
3
反応物 2
生成物 1
実験手順
5.36 g (12.0 mmol) 1-((1R,5S)-8-{2-[4-(3-fluorophenyl)piperidin-4-yl]ethyl}-8-azabicyclo[3.2.1]oct-3-yl)-2-methyl-1H-benzimidazole, 3.20 g (12.0 mmol) 2-chloro-4-fluoro-5-[(methylamino)sulfonyl]benzoic acid were combined following the general procedure in Example 5. 3.97 g recovered (47.6% yield). 1H NMR (300 MHz, DMSO-d6) δ 7.96-8.05 (br, 1H), 7.75-7.94 (m, 2 H), 7.38-7.56 (m, 3H), 7.24-7.30 (m, 2H), 7.07-7.18 (m, 3H), 4.48-4.60 (m, 1H), 3.91-4.03 (m, 1H), 3.23-3.49 (m, 6H), 3.04-3.13 (m, 1H), 2.52-2.60 (m, 4H), 2.33-2.44 (m, 2H), 2.12-2.32 (br, 2H), 2.01-2.09 (m, 2H), 1.76-1.95 (m, 8H), 1.60-1.66 (m, 2H). LC/MS m/z (M+H): 696
後処理
- custom3.97 g recovered (47.6% yield)
出典と根拠
- ORDレコード
- ord-a2385efcf2bd4466a4af66a87594291b
- 出典データセット
- uspto-grants-2010_01
- 特許番号
- US07645771B2
関連ノート
読み込み中…